about
WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodiesTargeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapyAPR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutationsIdentification of functional p53-binding motifs in the mouse wig-1 promoterPRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.Reactivation of mutant p53: a new strategy for cancer therapy.p53-induced apoptosis as a safeguard against cancer.Inactivation of Myc-induced p53-dependent apoptosis in human tumors.Expression of the p53 target Wig-1 is associated with HPV status and patient survival in cervical carcinomaMutant p53 reactivation by small molecules makes its way to the clinic.Novel cancer therapy by reactivation of the p53 apoptosis pathway.APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsp53 targets identified by protein expression profilingStrategies for therapeutic targeting of the p53 pathway in cancer.Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET.Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancerThe p53 target Wig-1 regulates p53 mRNA stability through an AU-rich elementTargeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53Mutant p53 rescue and modulation of p53 redox state.APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidaseRegulation of tumor suppressor p53 at the RNA level.Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulationThe p53 target Wig-1: a regulator of mRNA stability and stem cell fate?The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region.Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysisTP53: an oncogene in disguise.APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3σ.Understanding cell cycle and cell death regulation provides novel weapons against human diseases.Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells.PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival.Proteomic identification of p53-dependent protein phosphorylation.PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.Mutated and non-mutated TP53 as targets in the treatment of leukaemia.The p53-induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs.
P50
Q21145787-B6662F5E-52DE-423E-BECD-130AB4588FA6Q26766341-51F1E01B-6ADB-4970-ABCA-98D61620757AQ28284341-8C2CDA45-B151-4685-9E68-CED155457B9FQ28590032-1E574ADE-809C-45BB-9BC5-978276A30ED4Q30486972-AEC0EA36-47D8-4098-8151-7EC812EDFAD6Q30831001-9756ACD6-33F1-4BFA-BA77-019F52361B26Q31041084-F832B9F6-3286-4ED1-BEFA-E95BF6629DBDQ33547821-D40B56F1-F74B-46DC-A4B7-01AC3F593D2DQ33766705-C283A6F0-7B14-4018-A566-9BC3F22424A8Q34230638-8B2B5DE5-420E-4F87-A080-256CA759E29EQ34472748-7BF3FD88-B999-4EB3-ABAA-9CB9CA4C9789Q35157960-F408B162-3609-4E98-BDCF-B8F68009B729Q35597613-C084959A-36B3-43FF-8585-067E6A14CC81Q35667409-D43903A8-384A-4E23-9A9D-57AA0FC6E818Q35689748-C60ABEAD-0B47-4F6A-A812-CF3D4261810BQ36430162-19DAA153-466A-4AE3-B516-18803373C16AQ36598086-E02E8C11-D88E-4AC7-A7B1-CCC10EBBB9F2Q36904012-CC5D351C-F72C-4E70-9097-26F9B7E31C8CQ37412430-CC98CCFC-F9EF-4DAB-BCB0-F20AE8915117Q37488736-F7FDE2F7-3763-41FB-8D2F-48900E220384Q37562710-EA2BB753-1557-4A81-87D3-1ED58B36FB73Q37577458-BA873B23-B8B0-4B8E-959A-92684E5BD464Q37715822-17C98BD8-ACAD-42B0-8871-0D92685C75AFQ37736385-175EF350-3731-484E-AE42-A038876A5569Q37851826-B1169556-72A6-46B9-9130-7D6F09D56812Q38353041-CDD15B0B-0B02-41CC-92B2-9B8C12331D48Q38384363-DBCCAACC-17C4-435E-A512-0A6954E4BD4DQ38507513-30D9CD8B-C07C-4BA9-BFA7-D79FC41ABB67Q38851714-DE060316-C85A-4B2F-9F2D-1ADE2C6626A3Q39030008-2C9B21C8-2A11-492A-9720-BEB89C9694E2Q39218376-654E6605-B2A4-46D2-A14C-60635C36FBF9Q39445499-3E62B379-94BA-466A-8076-C415A69B50D5Q39694595-D496102F-16AA-4783-BDF6-D259AF44E8CEQ39709753-B6234725-6554-4F08-A4A1-1AC6EBFEDD85Q39857551-1AA24F99-B457-4693-B4A6-88DEE1BCC074Q39961048-1EE1EBC6-512E-40A4-8C63-65A1EABE2C37Q39988127-646B85F0-A545-46EB-BD6D-697211B4481FQ40018349-A24A28FF-011B-43CC-AC06-8598107AF14BQ40113704-B2E156BA-D66D-46A3-8C96-7BDA3ACE513AQ40255317-3A2F2ABA-1D5E-41BD-8094-94D48A29515D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Klas Wiman
@ast
Klas Wiman
@br
Klas Wiman
@co
Klas Wiman
@cs
Klas Wiman
@da
Klas Wiman
@de
Klas Wiman
@en
Klas Wiman
@es
Klas Wiman
@fr
Klas Wiman
@id
type
label
Klas Wiman
@ast
Klas Wiman
@br
Klas Wiman
@co
Klas Wiman
@cs
Klas Wiman
@da
Klas Wiman
@de
Klas Wiman
@en
Klas Wiman
@es
Klas Wiman
@fr
Klas Wiman
@id
prefLabel
Klas Wiman
@ast
Klas Wiman
@br
Klas Wiman
@co
Klas Wiman
@cs
Klas Wiman
@da
Klas Wiman
@de
Klas Wiman
@en
Klas Wiman
@es
Klas Wiman
@fr
Klas Wiman
@id
P106
P21
P31
P496
0000-0002-7113-524X